What Is Oxytocin?

Overview

Oxytocin (OXT) is a cyclic nonapeptide hormone and neuropeptide with the sequence Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, featuring a disulfide bridge between Cys¹ and Cys⁶ and a C-terminal amide (MW 1007.19 Da).[1]

Historical significance: The uterine-contracting properties of pituitary extracts were discovered by Sir Henry Dale in 1906. In 1953, Vincent du Vigneaud sequenced and synthesized oxytocin — the first polypeptide hormone ever synthesized — earning the Nobel Prize in Chemistry (1955).[2]

Oxytocin is synthesized in magnocellular and parvocellular neurons of the paraventricular (PVN) and supraoptic (SON) nuclei of the hypothalamus, derived from the OXT gene (chromosome 20) as an inactive prepro-oxytocin including carrier protein neurophysin I, and stored in the posterior pituitary.[3]

Structurally, oxytocin differs from arginine vasopressin (AVP) by only 2 amino acids (Ile³/Leu⁸ in OXT vs Phe³/Arg⁸ in AVP), driving significant cross-reactivity at vasopressin receptors.[3]

Evolutionary conservation: The OXT/AVP nonapeptide family is among the most evolutionarily conserved neuropeptide systems known, with homologs (vasotocin, isotocin, mesotocin) traced to early jawed vertebrates ~600 million years ago. The Ile³/Leu⁸ substitution that defines mammalian oxytocin emerged with placental mammals, coinciding with the evolution of the parturition-and-lactation reproductive program — supporting the hypothesis that the modern OXTR system was selected to coordinate uterine contractility, milk ejection, and maternal pup-bonding behavior into a single neuroendocrine cassette.[3][5]

Research framework: Contemporary investigation distinguishes peripheral oxytocin (uterine, mammary, cardiovascular, metabolic) from central oxytocin signaling (PVN/SON projections to amygdala, nucleus accumbens, ventral tegmental area, hippocampus, prefrontal cortex). Peripheral-to-central transfer across the blood-brain barrier is limited (<1% of dosed compound) but appears sufficient for behavioral effects in rodents and intranasally-dosed primates. Pharmacokinetic asymmetry — short plasma half-life (~3-5 min IV) versus extended CSF half-life (~28 min) and intranasal central exposure (~2.25-4 h) — has shaped the modern preclinical research program toward intranasal delivery and OXTR-selective analogs such as carbetocin.[3][21] Researchers studying related neuropeptide systems frequently cross-reference our Kisspeptin and Selank pages for parallel hypothalamic and anxiolytic neuropeptide pharmacology.